Amid Pricing Criticism, Marathon 'Pausing' Emflaza Launch

Company plans to meet with caregivers and consider other options before moving forward.

Marathon Pharmaceuticals LLC has decided to hold the launch of its newly approved Duchenne muscular dystrophy treatment Emflaza before it even started.

Company CEO Jeffrey Aronin wrote on the CureDuchenne blog Feb. 13 that after hearing concerns from patients about...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Drug Pricing

More from Scrip